Zaiding Pharmaceutical's partner Novocure announced that the US Food and Drug Administration has approved the simultaneous use of Optune Lua® with PD-1/PD-L1 inhibitors or docetaxel to treat adult patients with metastatic non-small cell lung cancer who have progressed during or after receiving platinum-containing treatment plans.

Zaiding Pharmaceutical's partner Novocure announced that the US Food and Drug Administration has approved the simultaneous use of Optune Lua® with PD-1/PD-L1 inhibitors or docetaxel to treat adult patients with metastatic non-small cell lung cancer who have progressed during or after receiving platinum-containing treatment plans.